



BOLETIM RAMB COVID-19

Número 39
24 de novembro de 2020

Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study

*Tayfun Caliskan
Bengu Saylan*

Em um momento em que há uma emergência mundial de saúde pública, é fundamental que o conhecimento científico gerado durante a pandemia chegue rapidamente à classe médica classe médica.

Dentro desta dinâmica a Revista da Associação Médica Brasileira (Ramb) está adotando uma série de medidas a fim de acelerar o processo editorial para publicação de artigos sobre a Covid-19. A partir de hoje (14/04/2020), a AMB publicará o Boletim Ramb Covid-19, que antecipará os artigos científicos selecionados pelos editores da Ramb sobre o tema.

“Os artigos foram escritos por especialistas e selecionados dentro dos critérios da Ramb para esclarecer temas fisiopatológicos, assim como oferecer orientações de prevenção e tratamento da doença. Dessa forma, esperamos colaborar com os médicos para o melhor atendimento aos seus pacientes, com a disponibilidade mais ágil desses artigos, antes de sua publicação na Ramb”, comenta Carlos Serrano Jr., editor-chefe da Ramb.

Para o diretor científico da AMB, Antonio Carlos Palandri Chagas, “neste momento ímpar vivido no mundo por conta da pandemia de Covid-19, a AMB cumpre seu papel de estar levando à comunidade científica brasileira os recentes artigos sobre os mecanismos fisiopatológicos e aspectos clínicos relevantes dessa situação que assola a saúde pública”.



Carlos Serrano Jr.



Antonio Carlos Palandri Chagas

EDITORIAL BOARD

EDITORS-IN-CHIEF

Carlos V. Serrano Jr.
José Maria Soares Jr.

CO-EDITOR

Wanderley M. Bernardo

MANAGING EDITOR

César Teixeira

ASSOCIATED EDITORS

Albert Bousso
Sérgio C. Nahas
Auro Del Giglio

SPECIALTY EDITORS

ACUPUNCTURE

Ari Ojeda Ocampo Moré
Pedro Cavalcante
Dirceu de Lavôr Sales
Marcia Lika Yamamura
Hildebrando Sábato
Fernando Claudio Genschow

ALLERGY AND IMMUNOLOGY

Herberto José Chong Neto
Luis Felipe Chiaverini Ensina
Pedro Francisco Giavina-Bianchi Júnior

ANAESTHESIOLOGY

Marcos Antonio Costa de Albuquerque
Maria Angela Tardelli
Maria José Carvalho Carmona
Rogean Rodrigues Nunes

ANGIOLOGY AND VASCULAR SURGERY

Marcelo Fernando Matielo
José Fernando Macedo
José Aderval Aragão
Arno Von Ristow
Daniel Mendes Pinto

CARDIOLOGY

Wolney de Andrade Martins
Olimpio Ribeiro França Neto
Otavio Rizzi Coelho Filho
Pedro Silvio Farsky
Humberto Graner Moreira

CARDIOVASCULAR

Eduardo Augusto Victor Rocha
João Carlos Ferreira Leal
Rui M. S. Almeida

CLINICAL PATHOLOGY / LABORATORY MEDICINE

Álvaro Pulchinelli Júnior
Maria Elizabete Mendes
Marinês Dalla Valle Martino
Silvana Maria Elói Santos

COLOPROCTOLOGY

Fábio G. Campos
Sergio Nahas

DERMATOLOGY

Mauro Yoshiaki Enokihara
Flávia Bittencourt

DIGESTIVE ENDOSCOPY

Adriana Safatle

DIGESTIVE SURGERY

Bruno Zilberstein
Nelson Andreollo
Oswaldo Malafaia
Carlos Eduardo Jacob

EMERGENCY MEDICINE

Hélio Penna Guimarães
Marcus Vinicius de Andrade
Júlio Marchini

ENDOCRINOLOGY AND METABOLISM

Márcio Mancini
Manoel Ricardo Alves Martins

Claudia Leite

Edna Frasson de S. Montero

Eduardo F. Borba

Elias Jirjoss Ilias

Isabela Giuliano

Lucia Pellanda

Paulo Kassab

Werther B. W. de Carvalho

Linamara Batistella

Dimas Ikeoki

Anna Andrei

Maria Laura Costa do Nascimento

Benedito Borges da Silva

FAMILY AND COMMUNITY MEDICINE

Thiago Sarti
Leonardo Fontenelle

GASTROENTEROLOGY

João Galizzi Filho
André Castro Lyra
Raquel Canzi Almada de Souza

GENERAL SURGERY

Luiz Carlos Von Bahten
Pedro Eder Portari Filho
Rodrigo Felipe Ramos

GERIATRICS AND GERONTOLOGY

Vitor Last Pintarelli

GYNAECOLOGY AND OBSTETRICS

César Eduardo Fernandes
Corintio Mariani Neto
Rosiane Mattar
Edmund Chada Baracat

HAND SURGERY

João Baptista Gomes dos Santos
Samuel Ribak
Antonio Carlos da Costa

HEAD AND NECK SURGERY

Antonio Jose Gonçalves
Flávio Carneiro Hojaij
José Guilherme Vartanian
Leandro Luongo Matos

HEMATOLOGY AND HEMOTHERAPY

Fernando Ferreira Costa

HOMEOPATHY

Silvia Irene Waisse Priven

INFECTIOUS DISEASES

Helio Bacha
Alexandre Vargas Schwarzbald

INTENSIVE CARE MEDICINE

Rosane Sonia Goldwasser
Cintia Magalhães Carvalho Grión
Claudio Piras

INTERNAL MEDICINE

Fernando Sabia Tallo
Abrão José Cury Junior

LEGAL MEDICINE AND MEDICAL EXAMINATIONS

Ivan Dieb Miziara
José Jozafra B. Freite

MASTOLOGY

Gil Facina
Rene Aloisio da Costa Vieira
Ruffo de Freitas Junior

MEDICAL GENETICS

Vera Lucia Gil da Silva Lopes

NEUROSURGERY

Luis Alencar B. Borba
Jean Gonçalves de Oliveira
José Carlos Esteves Veiga

José Marcus Rotta

Eberval Gadelha Figueiredo
Benedicto Oscar Colli

NEPHROLOGY

Andrea Pio de Abreu
Vinicius Daher Alvares Delfino
David Jose de Barros Machado

NEUROLOGY

Carlos Roberto de Mello Rieder
Marcondes Cavalcante França Jr.

NUCLEAR MEDICINE

Juliano Julio Cerci
Cristina Sebastião Matushita
George Barberio C. Filho
Rafael Willain Lopes

NUTROLOGY

Elza Daniel de Mello
Juliana Machado
Durval Ribas Filho

OCCUPATIONAL MEDICINE

Francisco Cortes Fernandes
Rosylane Nascimento das Mercês Rocha
Andrea Franco Amoras Magalhães

ONCOLOGY

Daniela Rosa
Markus Gifoni
Romualdo Barroso

OPHTHALMOLOGY

Keila Monteiro de Carvalho
Eduardo Melani Rocha

ORTHOPAEDICS AND TRAUMATOLOGY

Marco Kawamura Demange
Benno Ejnisman
Daniel Soares Baumfeld
Alex Guedes
Robinson Esteves Santos Pires

OTOLARYNGOLOGY

Marcio Nakanishi
Luciano Rodrigues Neves
Vinicius Ribas de Carvalho Duarte
Fonseca
Edson Ibrahim Mitre

PAEDIATRIC

Emanuel Savio Cavalcanti Sarinho
Debora Carla Chong e Silvia
Simone Brasil de Oliveira Iglesias

PAEDIATRIC SURGERY

Maria do Socorro Mendonça de Campos
Lisieux Eyer de Jesus
José Roberto de Souza Baratella

PATHOLOGY

Fernando Augusto Soares
Kátia Ramos Moreira Leite

PHYSICAL MEDICINE AND REHABILITATION

Silvia Verst
Eduardo Rocha
Luciana Dotta

INTERNATIONAL EDITORS

Frida Leonetti
Geltrude Mingrone
Giuseppe Barbaro
Marcelo Marotti
Walter Ageno
Michael Farkouh

JUNIOR EDITORS

Matheus Belloni Torsani
Hélio Amante Miot
Rubens Zeron
Luiz de Menezes Montenegro
Gustavo K. Matsui

Ligia Cattai

Marcus Yu Bin Pai

PLASTIC SURGERY

Ricardo Frota Boggio
Rodrigo Gouvea Rosique
Fabio Kamamoto

PREVENTIVE MEDICINE AND HEALTH ADMINISTRATION

Antonio Eduardo Fernandes D'Aguilar
Milton Massayuki Osaki
Helio Komagata

PSYCHIATRY

Antônio Geraldo da Silva
Itiro Shirakawa
Francisco Baptista Assumpção Junior
Leonardo Rodrigo Baldaçara
Sérgio Tamai

PULMONOLOGY / PHTHISIOLOGY

José Miguel Chatkin
Marcelo Fouad Rabahi
Rodrigo Luis Barbosa Lima
Rosemeri Maurici da Silva

RADIOTHERAPY

Arthur Accioly Rosa
Gustavo Nader Marta
Gustavo Viani Arruda
Mauricio Fraga da Silva

RADIOLOGY

Alair Sarmet
Valdir Muglia
Dante Luiz Escussato
Luciana Costa Silva
Claudia Leite
Manoel Rocha

RHEUMATOLOGY

Eduardo dos Santos Paiva

SPORTS MEDICINE

André Pedrinelli;
Fernando Carmelo Torres
Marcelo Bichels Leitão.

SURGICAL ONCOLOGY

Alexandre Ferreira Oliveira
Reitan Ribeiro
Gustavo Andrezza Laporte

TRAFFIC MEDICINE

José Heverardo da Costa Montal
Arlison de Souza Carvalho Junior
Egas Caparelli Moniz de Aragão Dáquer

THORACIC SURGERY

Darcy Pinto
Carlos Alberto Araujo
Ricardo Terra

UROLOGY

Eduardo Carvalhal
Gilberto Almeida
Stênio Zequi
Lucas Teixeira A. Batista
Francisco Bretas

**ASSOCIAÇÃO MÉDICA BRASILEIRA (BRAZILIAN MEDICAL ASSOCIATION)
MANAGEMENT BOARD 2017-2020**



PRESIDENT

Lincoln Lopes Ferreira (Minas Gerais)

1ST VICE-PRESIDENT

Diogo Leite Sampaio (Mato Grosso)

2ND VICE-PRESIDENT

Robson Freitas de Moura (Bahia)

VICE-PRESIDENTS

José Luiz Dantas Mestrinho – Mid-West (Federal District)

Arno Buertiner Von Ristow – Southeast (Rio de Janeiro)

Eduardo Francisco de Assis Braga – North (Tocantins)

Mauro Cesar Viana de Oliveira – Northeast (Maranhão)

Alfredo Floro Cantalice Neto – South (Rio Grande do Sul)

GENERAL SECRETARY

Antônio Jorge Salomão (São Paulo)

1ST SECRETARY

Carmita Helena Najjar Abdo (São Paulo)

1ST TREASURER

Miguel Roberto Jorge (São Paulo)

2ND TREASURER

José Luiz Bonamigo Filho (São Paulo)

CULTURAL DIRECTOR

Fernando Antonio Gomes de Andrade (Alagoas)

DIRECTOR OF CORPORATE RELATIONS

Carlos Alfredo Lobo Jasmin (Rio de Janeiro)

DIRECTOR OF INTERNATIONAL RELATIONS

Eduardo Nagib Gaudi (Rio de Janeiro)

SCIENTIFIC DIRECTOR

Antonio Carlos Palandri Chagas (São Paulo)

ACADEMIC DIRECTOR

Maria José Martins Maldonado (Mato Grosso do Sul)

DIRECTOR OF MEMBER SUPPORT SERVICES

Marcio Silva Fortini (Minas Gerais)

DIRECTOR OF PARLIAMENTARY AFFAIRS

Débora Eugenia Braga Nóbrega Cavalcanti (Paraíba)

**RAMB - REVISTA DA ASSOCIAÇÃO MÉDICA BRASILEIRA
(JOURNAL OF THE BRAZILIAN MEDICAL ASSOCIATION)**

RAMB

EDITORS-IN-CHIEF: Carlos V. Serrano Jr. and José Maria Soares Jr.

CO-EDITOR: Wanderley M. Bernardo

MANAGING EDITOR: César Teixeira

E-MAIL: ramb@amb.org.br

WEBSITE: www.amb.org.br

Address: Rua São Carlos do Pinhal, 324

Bela Vista – São Paulo

Postal Code: 01333-903

Phone no.: (+55 11) 3178-6800 Ext. 177

The RAMB, Journal of The Brazilian Medical Association, is an official publication of the Associação Médica Brasileira (AMB – Brazilian Medical Association), indexed in Medline, Science Citation Index Expanded, Journal Citation Reports, Index Copernicus, Lilacs, and Qualis B2 Capes databases, and licensed by Creative Commons®. Registered in the 1st Office of Registration of Deeds and Documents of São Paulo under n. 1.083, Book B, n. 2.

Publication norms are available on the website www.amb.org.br

All rights reserved and protected by Law n. 9.610 – 2/19/1998. No part of this publication may be reproduced without prior written authorization of the AMB, whatever the means employed: electronic, mechanical, photocopying, recording or other.

THE RAMB IS INDEXED IN SCIELO - SCIENTIFIC ELECTRONIC LIBRARY ONLINE.



TIMBRO EDITORA

PUBLISHER: Rodrigo Aguiar

AUTHORIZING EDITOR: Luciano Bauer Grohs

EDITOR: Celina Maria Morosino Lopes

PRODUCER: Maria Fortes

EDITORIAL PRODUCER: Helvânia Ferreira

ENGLISH TRANSLATION OF ARTICLES: Alpha & Omega

REFERENCE REVIEWER: Rosângela Monteiro

PROOFREADING: Hebe Ester Lucas e Alpha & Omega

GRAPHIC DESIGN: Angela Mendes e Murilo M. Camargo



The advertisements and opinions published in the Ramb are the sole responsibility of the advertisers and authors. The AMB and Timbro Comunicação are not responsible for its content.

Smoking and comorbidities are associated with COVID-19 severity and mortality in 565 patients treated in Turkey: a retrospective observational study

 Tayfun Caliskan¹
 Bengu Saylan²

1. Assistant Professor, Department of Pulmonology, Sultan 2.Abdulhamit Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
2. Pulmonologist, Department of Pulmonology, Sultan 2.Abdulhamit Han Training and Research Hospital, Health Sciences University, Istanbul, Turkey.

SUMMARY

OBJECTIVE: We aimed to explore the prevalence of smoking rates and comorbidities and evaluate the relationship between them and disease severity and mortality in inpatients with COVID-19.

METHODS: COVID-19 patients were divided into the following groups: clinic group, intensive care unit (ICU) group, survivors, and non-survivors. Non-COVID-19 patients were included as a control group. The groups were compared.

RESULTS: There was no difference between patients with and without COVID-19 in terms of smoking, asthma, diabetes, dementia, coronary artery disease (CAD), hypertension, chronic renal failure and arrhythmia ($p>0.05$). Older age (Odds ratio (OR), 1.061; 95% confidence interval (CI): 1.041-1.082; $p<0.0001$), chronic obstructive pulmonary disease (COPD) (OR, 2.775; 95% CI: 1.128-6.829; $p=0.026$) and CAD (OR, 2.696; 95% CI: 1.216-5.974; $p=0.015$) were significantly associated with ICU admission. Current smoking (OR, 5.101; 95% CI: 2.382-10.927; $p<0.0001$) and former smoking (OR, 3.789; 95% CI: 1.845-7.780; $p<0.0001$) were risk factors for ICU admission. Older age (OR; 1.082; 95% CI: 1.056-1.109; $p<0.0001$), COPD (OR, 3.213; 95% CI: 1.224-8.431; $p=0.018$), CAD (OR, 6.252; 95% CI: 2.171-18.004; $p=0.001$) and congestive heart failure (CHF) (OR, 5.917; 95% CI 1.069-32.258; $p=0.042$), were significantly associated with mortality. Current smoking (OR, 13.014; 95% CI: 5.058-33.480; $p<0.0001$) and former smoking (OR, 6.507; 95% CI 2.731-15.501; $p<0.0001$) were also risk factors for mortality.

CONCLUSION: Smoking, older age, COPD, and CAD were risk factors for ICU admission and mortality in patients with COVID-19. CHF was not a risk factor for ICU admission; however, it was a risk factor for mortality.

KEYWORDS: Smoking, Mortality, COVID-19, Comorbidity, Severity

RESUMO

OBJETIVO: Buscamos explorar as taxas de prevalência de tabagismo e de comorbidades e avaliar a relação entre elas e a severidade e mortalidade da doença em pacientes hospitalizados com COVID-19.

MÉTODOS: Pacientes com COVID-19 foram divididos nos seguintes grupos: grupo clínico, grupo da unidade de terapia intensiva (UTI), grupo de sobreviventes e não-sobreviventes. Pacientes sem COVID-19 foram incluídos em um grupo de controle. Os grupos foram comparados.

RESULTADOS: Não houve diferença entre os pacientes com e sem COVID-19 em termos de tabagismo, asma, diabetes, demência, doença arterial coronariana (DAC), hipertensão arterial, insuficiência renal crônica e arritmia ($p>0,05$). Idade mais avançada (odds ratio (OR), 1,061; 95% de intervalo de confiança (IC): 1,041-1,082; $p<0,0001$), doença pulmonar obstrutiva crônica (DPOC) (OR, 2,775; 95% IC: 1,128-6,829; $p=0,026$) e DAC (OR, 2,696; 95% IC: 1,216-5,974; $p=0,015$) estavam significativamente associados com a admissão na UTI. O tabagismo atual (OR, 5,101; 95% IC: 2,382-10,927; $p<0,0001$) e tabagismo prévio (OR, 3,789; 95% IC: 1,845-7,780; $p<0,0001$) foram fatores de risco para admissão na UTI. Idade mais avançada (OR; 1,082; 95% IC: 1,056-1,109; $p<0,0001$), DPOC (OR, 3,213; 95% IC: 1,224-8,431; $p=0,018$), DAC (OR, 6,252; 95% IC: 2,171-18,004; $p=0,001$) e insuficiência cardíaca congestiva (ICC) (OR, 5,917; 95% IC 1,069-32,258; $p=0,042$) estavam significativamente associados com mortalidade. O tabagismo atual (OR, 13,014; 95% IC: 5,058-33,480; $p<0,0001$) e o tabagismo prévio (OR, 6,507; 95% IC 2,731-15,501; $p<0,0001$) também foram fatores de risco para mortalidade.

CONCLUSÃO: O tabagismo, a idade avançada, DPOC e DAC foram fatores de risco para admissão na UTI e mortalidade em pacientes com COVID-19. ICC não foi um fator de risco para admissão na UTI; no entanto, foi um fator de risco para mortalidade.

PALAVRAS-CHAVE: Tabagismo, Mortalidade, COVID-19, Comorbidade, Gravidade

INTRODUCTION

The COVID-19 pandemic, caused by SARS-CoV-2 is still ongoing and has caused hundreds of thousands of deaths worldwide. The lack of currently approved treatment and vaccination makes it difficult to fight against the disease. Identifying and understanding the risk factors for mortality and poor prognosis of the disease will determine the clinical approach and treatments to be applied to patients.

In 2019, around a fourth (24.9%) of the global population (both sexes combined) aged 15 years and older were current users of some form of tobacco, and more than 8 million people died from tobacco use including both tobacco smoking and smokeless tobacco use in 2017.¹ Active smoking has been reported to increase the risk of viral respiratory diseases.² Smokers have an increased risk for community-acquired pneumonia.³ About 20% of COVID-19 patients develop pulmonary infiltrates and some of these will develop very severe disease, hypoxia, and progression to ARDS.⁴ The angiotensin-converting enzyme (ACE-2) protein, which is expressed on the surface of lung type-2 pneumocytes, is an entry receptor for SARS-CoV-2.⁴ ACE-2 gene expression and is higher in smokers than in non-smokers, which may explain the increased

risk of severe COVID-19 in this population.⁵ On the other hand, Lippi et al. reported that smoking was not associated with COVID-19 severity.⁶

Comorbidities were associated with the severity of COVID-19.⁷ The fatality rate also increased in patients with comorbidities.⁸ Older age, male sex, and comorbidities including chronic cardiac disease, non-asthmatic chronic pulmonary disease, chronic kidney disease, liver disease, and obesity were associated with higher in-hospital mortality.⁹ There are conflicting results in studies for the prevalence of comorbidities and the factors affecting COVID-19 severity and mortality. The interpretation of the effects of smoking on COVID-19 is difficult, because one of the factors affecting smoking status is gender, and cardiovascular diseases are more common in smokers. Combined hormonal contraception with other risk factors increases venous thromboembolism risk, especially in patients hospitalized with COVID-19.¹⁰ Menopausal hormone therapy also affects the risk of cardiovascular diseases.¹¹

We aimed to explore the prevalence of smoking rates and comorbidities and evaluate the relationship between smoking and comorbidities with disease severity and mortality in inpatients with and without COVID-19 in this study.

METHODS

This retrospective observational study was conducted in Sultan 2, in the Abdulhamit Han Training & Research Hospital, which has also been a COVID-19 reference center during the pandemic, in Istanbul, Turkey, between March 15 and May 10, 2020. The study was approved by the local ethics committee (179/May 12, 2020). Adult patients (≥ 18 years old) diagnosed with COVID-19 by polymerase chain reaction (PCR) and whose COVID-19 diagnosis was based on clinical, laboratory, and radiological findings, especially with chest computed tomography findings,

despite COVID-19 PCR negativity were included. Non-COVID-19 patients who were hospitalized in the department of pulmonology due to diseases other than COVID-19 were included as the control group. The data were extracted from electronic medical records of the hospital. Age, smoking status, comorbidities including hypertension, coronary artery disease (CAD), arrhythmia, congestive heart failure (CHF), diabetes, chronic obstructive pulmonary disease (COPD), asthma, dementia, and chronic renal failure (CRF) were recorded based on patients' self-reporting or information received from patient relatives. The smoking status was classified as current smoker, former smoker, and never smoked. Former smokers were patients who reported having smoked ≥ 100 cigarettes during their lifetime and were not smoking for at least the past three months. The patients with COVID-19 were divided into two groups: a clinic group and an intensive care unit (ICU) group. In addition, the patients were divided into two groups: survivors and non-survivors. The groups were compared in terms of smoking, age, and comorbidities.

Patient data collected in the study were analyzed with the IBM Statistical Package for the Social Sciences

(SPSS) for Windows 21.0 package program (Statistical Package for the Social Sciences, Chicago, IL, USA). Discrete data is given as frequency and percentage. The mean \pm standard deviation for continuous data is given as descriptive value. The Mann Whitney U-test was used to compare the two groups. The Pearson Chi-Square Test and Fisher's Exact Test were used to compare the two categorical groups. Logistic Regression Analysis was used to examine the risk factors for mortality and intensive care unit admission. The results were considered statistically significant when the p-value was less than 0.05.

RESULTS

The study included 565 patients hospitalized with COVID-19 and 248 patients hospitalized with non-COVID-19 diseases. The mean ages of the patients with and without COVID-19 were 48.0 ± 19.7 and 52.0 ± 21.1 (Table 1). There was no statistically significant difference between patients with and without COVID-19 in terms of smoking, asthma, diabetes, dementia, CAD, hypertension, CRF, and arrhythmia ($p > 0.05$). Non-COVID-19 patients were older than COVID-19 patients ($p = 0.014$). COPD and CHF were more common

TABLE 1. COMPARISON BETWEEN PATIENTS WITH AND WITHOUT COVID-19

	COVID-19 (N= 565) N (%)	Non-COVID-19 (N=248) N (%)	p
Age, median (IQR)	48 \pm 19.664	52 \pm 21.105	0.014
Current smoker	118 (20.9)	47 (18.9)	0.738
Former smoker	79 (14.0)	33 (13.3)	
Never smoked	368 (65.1)	169 (67.9)	
COPD	37 (6.5)	47 (18.9)	<0.0001
Asthma	21 (3.7)	8 (3.2)	0.839
Diabetes	72 (12.7)	41 (16.5)	0.186
Dementia	12 (2.1)	3 (1.2)	0.572
CAD	42 (7.4)	11 (4.4)	0.124
Hypertension	128 (22.7)	53 (21.3)	0.715
Chronic renal failure	12 (2.1)	9 (3.6)	0.234
CHF	14 (2.5)	24 (9.6)	<0.0001
Arrhythmia	14 (2.5)	8 (3.2)	0.639

IQR: interquartile range; COPD: Chronic pulmonary obstructive disease; CAD: Coronary artery disease; CHF: Congestive heart failure.

TABLE 2. SMOKING STATUS AND COMORBIDITIES OF THE PATIENTS WITH COVID-19

	Clinic (N= 474) N (%)	ICU (N=91) N (%)	p	Survivors (N= 490) N (%)	Non-survivors (N=75) N (%)	p
Current smoker	96 (20.3)	22 (24.2)	<0.0001	97 (19.8)	21 (28.0)	<0.0001
Former smoker	45 (9.5)	34 (37.4)		48 (9.8)	31 (41.3)	
Never smoked	333 (70.3)	35 (38.5)		345 (70.4)	23 (30.7)	
Age, median (IQR)	44 (26-57)	69 (58-79)	<0.0001	44 (27-57)	70 (62-80)	<0.0001
COPD	12 (2.5)	25 (27.5)	<0.0001	12 (2.4)	25 (33.3)	<0.0001
Asthma	17 (3.6)	4 (4.4)	0.761	17 (3.5)	4 (5.3)	0.506
Diabetes	49 (10.3)	23 (25.3)	<0.0001	54 (11.0)	18 (24.0)	0.004
Dementia	7 (1.5)	5 (5.5)	0.030	7 (1.4)	5 (6.7)	0.013
CAD	22 (4.6)	20 (22.0)	<0.0001	24 (4.9)	18 (24.0)	<0.0001
Hypertension	81 (17.1)	47 (51.6)	<0.0001	88 (18.0)	40 (53.3)	<0.0001
Chronic renal failure	6 (1.3)	6 (6.6)	0.006	7 (1.4)	5 (6.7)	0.013
CHF	9 (1.9)	5 (5.5)	0.059	9 (1.8)	5 (6.7)	0.027
Arrhythmia	8 (1.7)	6 (6.6)	0.015	8 (1.6)	6 (8.0)	0.006

ICU: Intensive care unit; IQR: interquartile range; COPD: Chronic pulmonary obstructive disease; CAD: Coronary artery disease; CHF: Congestive heart failure.

TABLE 3. MULTIVARIATE LOGISTIC REGRESSION ANALYSIS OF VARIABLES RELATED TO ICU ADMISSION AND MORTALITY

Risk factor	For ICU admission		For mortality	
	OR (%95 CI)	P-value	OR (%95 CI)	P-value
Former smoker	3.789 (1.845-7.780)	<0.0001	6.507 (2.731-15.501)	<0.0001
Current smoker	5.101 (2.382-10.927)	<0.0001	13.014 (5.058-33.480)	<0.0001
Age	1.061 (1.041-1.082)	<0.0001	1.082 (1.056-1.109)	<0.0001
COPD	2.775 (1.128-6.829)	0.026	3.213 (1.224-8.431)	0.018
Diabetes	1.152 (0.553-2.396)	0.706	1.037 (0.445-2.421)	0.932
Dementia	1.249 (0.315-4.952)	0.751	1.762 (0.408-7.607)	0.448
CAD	2.696 (1.216-5.974)	0.015	6.252 (2.171-18.004)	0.001
Hypertension	1.571 (0.818-3.016)	0.175	1.458 (0.690-3.079)	0.323
Chronic renal failure	3.685 (0.983-13.811)	0.053	3.982 (0.939-16.891)	0.061
CHF	NA	NA	5.917 (1.069-32.258)	0.042
Arrhythmia	1.649 (0.446-6.097)	0.453	2.804 (0.689-11.412)	0.150

ICU: Intensive care unit; OR: Odds ratio; CI: Confidence interval; COPD: Chronic pulmonary obstructive disease; CAD: Coronary artery disease; CHF: Congestive heart failure; NA: Not applicable.

in non-COVID-19 patients than in patients with COVID-19 (18.9%, 9.6% vs. 6.5%, 2.5%, $p < 0.001$). Hypertension (22.7%), diabetes (12.7%), CAD (7.4%) and COPD (6.5%), were the most common comorbidities in patients with COVID-19. The ICU group had a significantly higher proportion of patients with current and former smoking than the clinic group (24.2%, 37.4%, vs. 20.3%, 9.5%, $p < 0.0001$) (Table 2). The patients in the ICU group were significantly older than those in the clinic group ($p < 0.0001$). COPD, diabetes, dementia, CAD,

hypertension, CRF, and arrhythmia were found to be significantly more common in the ICU group than in the clinic group ($p < 0.05$). There was no difference between the two groups for asthma and CHF ($p > 0.05$). The results of the logistic regression analysis demonstrated that older age [Odds ratio (OR), 1.061; 95% confidence interval (CI): 1.041-1.082; $p < 0.0001$], COPD (OR, 2.775; 95% CI: 1.128-6.829; $p = 0.026$), and CAD (OR, 2.696; 95% CI: 1.216-5.974; $p = 0.015$) were significantly associated with ICU admission (Table 3). Current smoking (OR, 5.101;

95% CI: 2.382-10.927; $p < 0.0001$) and former smoking (OR, 3.789; 95% CI: 1.845-7.780; $p < 0.0001$) were risk factors for ICU admission. Diabetes, dementia, hypertension, CRF, and arrhythmia were not significantly associated with ICU admission.

Non-survivors were older than survivors ($p < 0.0001$) (Table 2). Current smokers and former smokers were more common in non-survivors ($p < 0.0001$). COPD, diabetes, dementia, CAD, hypertension, CRF, CHF, and arrhythmia were significantly more common among non-survivors than in survivors ($p < 0.05$). There was no difference between non-survivors and survivors in terms of asthma ($p > 0.05$). The logistic regression analysis indicated that older age (OR; 1.082; 95% CI: 1.056-1.109; $p < 0.0001$), COPD (OR, 3.213; 95% CI: 1.224-8.431; $p = 0.018$), CAD (OR, 6.252; 95% CI: 2.171-18.004; $p = 0.001$), and CHF (OR, 5.917; 95% CI 1.069-32.258; $p = 0.042$), were significantly associated with mortality (Table 3). Current smoking (OR, 13.014; 95% CI: 5.058-33.480; $p < 0.0001$) and former smoking (OR, 6.507; 95% CI 2.731-15.501; $p < 0.0001$) were risk factors for mortality. Diabetes, dementia, hypertension, CHF, and arrhythmia were not significantly associated with mortality ($p > 0.05$).

DISCUSSION

In this study, the prevalence of comorbidities and the factors affecting COVID-19 prognosis were examined. Revealing these risk factors can be decisive and guide clinicians towards the effective treatment and proper management of patients with COVID-19.

There was no difference in smoking between COVID-19 and non-COVID-19 patients. The rate of active smokers and former smokers were significantly higher among patients who were admitted to the ICU. Current smoking was associated with 5-fold and 13-fold increased risks respectively for ICU admission and mortality in the present study.

Former smokers were 3.7 times more likely to be admitted to ICU and 6.5 times more likely to die than non-smokers. Lippi et al. reported that smoking did not affect the severity of COVID-19.⁶ However, active cigarette smoking was associated with the risk of severe COVID-19 in the re-analysis of the data.¹² In studies conducted in COVID-19 patients in China, smoking rates were lower than among the general population.¹³ This may be related to the inability to receive patient data, record data, and health system deficiencies during the pandemic. In the study by Zhou F et al., there was no difference between patients who recovered and died in terms of active smoking (4% vs. 9% $p = 0.21$).¹⁴ Conversely, Guan W et al. indicated that the smoking rate was higher in patients with severe COVID-19 patients.¹⁵

COPD was more common in non-COVID-19 patients than in COVID-19 patients, but this was due to the fact that patients were hospitalized in the department of pulmonology. In a meta-analysis, patients with COPD had a 5-fold increased risk of severe COVID-19.¹⁶ Patients with COPD have also a higher risk for in-hospital mortality due to COVID-19.¹⁷ The results of the present study were compatible with previous reports, and COPD was a risk factor for ICU admission and mortality. The increased risk for severe COVID-19 in patients with asthma has not been proven in studies yet. The prevalence of asthma in COVID-19 patients in China was lower than in the general population.¹⁸ Asthma was not a risk factor for ICU admission and mortality in the present study.

Hypertension was reported to be associated with a 2.5-fold increased risk for COVID-19 severity and mortality, especially in the elderly.¹⁹ The mortality risk of hypertensive COVID-19 patients was increased, with an OR of 3.36.²⁰ Although hypertension was the most common comorbidity in the present study, it was not a risk factor

for ICU admission and mortality. According to this study, arrhythmia was not a risk factor for ICU admission and mortality. CAD was a risk factor for both ICU admission and mortality, and CHF was not a risk factor for ICU admission but was a risk factor for mortality in the present study. Non-COVID-19 patients were older patients who needed inpatient treatment; therefore CHF was more common in non-COVID-19 patients than in COVID-19 patients. Cardiac injury was a common comorbidity in COVID-19 patients treated in a hospital in Wuhan and increased mortality.²¹ ACE-2 levels were higher in patients with cardiovascular disease.²² On the other hand, SARS-CoV-2 can reduce ACE-2, causing excessive accumulation of angiotensin II, which induces myocarditis and acute respiratory distress syndrome.²²

In a previous study, diabetes was associated with COVID-19 severity and mortality, and this was particularly evident in younger and less hypertensive patients.²³ Diabetes was the second most common comorbidity in the present study but it was not a risk factor for ICU admission and mortality. CRF has been associated with an increased risk of severe COVID-19.²⁴ Another study concluded that renal disease did not increase the risk of COVID-19.²⁵ CRF was not a risk factor for ICU admission and mortality in this study. Patients with Alzheimer's disease and related dementias have an increased risk of COVID-19.²⁶ Therefore, concerns have arisen regarding these patients during the COVID-19 pandemic. Dementia was not a risk factor for ICU admission and mortality in the present study. It has been reported that in-hospital mortality was higher in patients over 65 years old with COVID-19.¹⁷ Older age was also a risk factor for ICU admission and mortality in the present study.

The most important limitation of this study was its retrospective design. Therefore, data about patients'

medical records in the hospital system were used. Comorbidities were also checked from the e-pulse system to prevent a lack of data. Missing data about smoking status was completed by contacting the patient or relatives by phone.

CONCLUSION

Smoking, older age, COPD, and CAD were risk factors for ICU admission and mortality in inpatients treated for COVID-19. Asthma, diabetes, dementia, hypertension, CRF, and arrhythmia were not associated with ICU admission and mortality. CHF was not a risk factor for ICU admission; however, it was a risk factor for mortality.

Sources of funding

The authors received no financial support for the research and/or authorship of this article.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics

Informed consent was waived because of the retrospective nature of the study. This study was approved by the Ethics Committee of the Umraniye Training and Research Hospital (No: 179, Date: May 12, 2020).

Author's Contribution

TC, BS designed the study; BS collected the data; TC performed the literature review; BS performed the statistical analysis; TC wrote the paper; TC, BS performed the critical review of the manuscript. ■

Submitted Date: 02-Sep-2020

Accepted Date: 02-Sep-2020

CORRESPONDING AUTHOR:

Tayfun Caliskan
Department of Pulmonology, Sultan 2. Abdulhamit Han Training and Research Hospital, Health Sciences University
Tibbiye Avenue, Selimiye Street, Uskudar, Istanbul, Turkey – 34688
Tel: +90 021 6542-2020
E-mail: drtcaliskan@yahoo.com

REFERENCES

1. World Health Organization. Defining sexual health. Geneva: World Health Organization; 2020. [cited 2020 May 17]. Available from: <https://www.who.int/WHO-global-report-on-trends-in-prevalence-of-tobacco-use-2000-2025>, third edition. Geneva: World Health Organization: 2019.
2. Lawrence H, Hunter A, Murray R, Lim WS, McKeever T. Cigarette smoking and the occurrence of influenza - Systematic review. *J Infect.* 2019;79(5):401-6.
3. Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. *PLoS One.* 2019;14(7):e0220204.
4. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J.* 2020;55(4):2000607.
5. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med.* 2020;201(12):1557-9.
6. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med.* 2020;75:107-8.
7. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020;94:91-5.
8. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020;10.1001/jama.2020.2648.
9. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ.* 2020;369:m1985.
10. Carbonel AAF, Simões RS, Girão MJBC, Soares Júnior JM, Baracat EC. Cardiovascular system and estrogen in menopause. *Rev Assoc Med Bras (1992).* 2020;66(2):97-8.
11. Ferreira-Filho ES, de Melo NR, Sorpreso ICE, Bahamondes L, Simões RDS, Soares Júnior JM, Baracat EC. Contraception and reproductive planning during the COVID-19 pandemic. *Expert Rev Clin Pharmacol.* 2020;13(6):615-22.
12. Guo FR. Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis. *Tob Induc Dis.* 2020;18:37.
13. Farsalinos K, Barbouni A, Niaura R. Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? *Intern Emerg Med.* 2020;15(5):845-52.
14. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-62.
15. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708-20.
16. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). *Respir Med.* 2020;167:105941.
17. Alqahtani JS, Oyelade T, Aldhahir AM, Alghamdi SM, Almeahadi M, Alqahtani AS, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. *PLoS One.* 2020;15(5):e0233147.
18. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020;146(1):110-8.
19. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. *Pol Arch Intern Med.* 2020;130(4):304-9.
20. Zuin M, Rigatelli G, Zuliani G, Rigatelli A, Mazza A, Roncon L. Arterial hypertension and risk of death in patients with COVID-19 infection: Systematic review and meta-analysis. *J Infect.* 2020;81(1):e84-e86.
21. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiol.* 2020;5(7):802-10.
22. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations? *Clin Infect Dis.* 2020;71(15):870-4.
23. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. *Diabetes Metab Syndr.* 2020;14(4):395-403.
24. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. *Int Urol Nephrol.* 2020;52(6):1193-4.
25. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging (Albany NY).* 2020;12(7):6049-57.
26. Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and Mitigating the Impact of the COVID-19 Pandemic on Alzheimer's Disease and Related Dementias. *Am J Geriatr Psychiatry.* 2020;28(7):712-21.